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Abstract 
Lymphadenopathy is common in HIV-infected individuals as lymphoid tissue is a major 
target and reservoir of the Human immunodeficiency virus (HIV).  Lymphadenopathy may 
occur at any stage of HIV infection.  Lymphadenopathy is also a common clinical problem 
confronting the primary care physician. When lymphadenopathy occurs in the setting of 
underlying immunodeficiency, both benign and malignant aetiologies need to be considered.  
Indeed, in our study of 43 patients with HIV seropositivity, where a lymph node biopsy was 
performed (i.e. in 40 patients), TB was the most common cause of significant 
lymphadenopathy (16/40 - 60%), followed by malignancy (10/40 - 25%). However, 9/40 
patients (22.5%) in this group, also had reactive lymphadenopathy, which may or may not be 
related to the HIV. 
The primary objectives of this study were:  i) to define the causes and the clinical patterns of 
presentation of lymphadenopathy in an HIV sero-positive population.  Secondary objectives 
were:  i)  To review the appropriateness of the investigations that may suggest or exclude a 
possible cause of the lymphadenopathy and ii) To correlate the results of a FNA and/or 
lymph node biopsy when this was  performed.  Furthermore, iii) it was questioned whether it 
was possible to identify criteria indicating a need for a FNA and/or a lymph node biopsy. 
A total of 43 Black African adult patients, 21 males (49%) and 22 females (51%), were 
prospectively studied during 2004 and 2005.  The median age was 33 years (range 16-52 
years).   The median duration of lymphadenopathy was 16weeks (3-52 weeks). 
A history of constitutional symptoms was most common among the patients diagnosed with 
TB, but did not reach statistical significance.  In our study, the finding of lymphadenopathy in 
the cervical and axillary regions did not differentiate between malignancy, TB and reactive 
nodes. However, the presence of these nodes was suggestive of significant pathology i.e. 
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malignancy or TB.  The presence of hard nodes was more in keeping with a diagnosis of 
malignancy and/or TB.  The presence of matted nodes was classical of TB. 
In the ten patients diagnosed with malignancy, three had significant peripheral 
lymphadenopathy at only a single site, emphasizing the point that malignancy may present 
with localised adenopathy as well as generalised adenopathy.  The lymph node biopsy in the 
three patients with localised adenopathy showed non-Hodgkin’s lymphoma.  
Lymphadenopathy in HIV positive patients does not seem to follow any specific clinical 
pattern. The nodes, in addition to the presence of malignancy, TB or other pathology may be 
distorted by the presence of PGL.  This concept may still be true if one considers that some of 
the patients did indeed have more than one pathology in their lymph nodes.  One patient was 
diagnosed as having a metastatic neuroendocrine tumour on the first FNA and TB on a 
second FNA.  Lymph node biopsy was consistent with a neuroendocrine tumour.  However, 
the patient also tested positive for acid fast bacilli on a sputum sample.  Similarly, another 
patient had KS on one lymph node and reactive changes on another node from the same 
biopsy site.  A third patient had TB and reactive lymphadenopathy from the same biopsy site. 
Even though there was no correlation between chest radiographs and lymph node biopsy 
pathology in our study, the finding of intra-thoracic lymphadenopathy suggested more 
significant pathology, such as TB or malignancy.  
A patient with unexplained cytopenias, especially with a pancytopenia should ideally have a 
bone marrow aspirate and trephine biopsy to clearly elucidate the underlying pathology.  
Interestingly in our study, a patient diagnosed with reactive lymphadenopathy on FNA and 
subsequently shown to have Castleman’s disease on lymph node biopsy, had a granuloma on 
bone marrow trephine consistent with TB.    
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A relative monocytosis was suggestive of malignancy in our study, but may also be an 
indication of viral latency, as most of these patients with monocytosis also had a CD4+ 
lymphocyte count above 200 cells/mm
3
.   
In our study, thirty patients had both a FNA and a lymph node biopsy for comparison.  
Comparing FNA with lymph node biopsy as the true positive, eleven patients were diagnosed 
with TB, four with malignancy, three as reactive and two as having other aetiologies of their 
lymphadenopathy.       
In the discrepant group of ten patients comparing FNA to Biopsy, five patients were 
diagnosed as having reactive lymph nodes on FNA, but the biopsy confirmed two with 
Castleman’s disease, two with NHL and one with TB.  One patient diagnosed as TB on FNA, 
had KS on biopsy.  Another patient with a lymphoepithelial cyst on FNA had reactive 
lymphadenopathy on biopsy.  A further patient diagnosed with TB on FNA had a sub-optimal 
lymph node biopsy.  
The differences in FNA and biopsy results could be explained as ‘errors’ of sampling.  In 
other words the FNA and biopsy were done at different sites in the same patient, and 
therefore these patients potentially had more than one pathological cause for their 
lymphadenopathy. Also, less tissue was available for review from the FNA specimen and 
immunohistochemical stains were not possible on the paucity of FNA material available.  
In the patients who had a lymph node biopsy, sixteen had TB, ten were diagnosed with 
malignancy (seven with NHL, two with KS and one with a neuroendocrine tumour).  The 
other group included two patients with Castleman’s disease, one with a lymphoepithelial cyst, 
one with fibrous tissue and one as having a suboptimal biopsy.  One patient had a biopsy 
which showed KS on one lymph node and a second node as having reactive features. A 
second patient had a diagnosis of TB and reactive lymphadenopathy on the same biopsy.  
Nine patients had reactive lymphadenopathy on biopsy. Using chi-square analysis, the 
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specificity and sensitivity of FNA was compared to the lymph node biopsy results.  In 
general, the low specificity and sensitivity in the different groups with the wide confidence 
intervals may be due to the small sample size in our patient population.  Nevertheless, when 
comparing FNA to lymph node biopsy for the diagnosis of malignancy, the specificity and 
sensitivity was 100% and 43% respectively, with wide confidence intervals. This indicates 
that although a positive result for malignancy on FNA is highly specific, FNA for the 
diagnosis of malignancy is much less sensitive and a significant number of patients could be 
missed if the diagnosis is based on the FNA only. The specificity and sensitivity for the 
diagnosis of TB was 86% and 95% respectively (FNA is less specific for TB, but more 
sensitive).  Reactive lymphadenopathy had a lower specificity and sensitivity of 80% and 
60% respectively.  Similarly, the specificity and sensitivity for the diagnosis of other 
pathologies was 86% and 40% respectively. These results underline the importance of 
performing a lymph node biopsy (which remains the ‘gold standard’), more particularly 
where malignancy is suspected or where a reactive FNA result may not be sensitive enough 
to exclude a more definitive diagnosis for the lymphadenopathy. 
The clinical haematology department receives referrals of lymphoma patients from other 
hospitals and other departments within the hospital (such as surgery, ENT etc).  Many of 
these patients are referred with a biopsy proven lymphoma.  Morever, 60-70% of all patients 
with lymphoma(both NHL and HD) are HIV sero-positive.  As a result of this pattern of 
referral, the reflection of the cause of lymphadenopathy at this hospital may not have been 
obtained in this study.  This should be regarded as a limitation of the study. Other 
shortcomings of this study include the small sample size, making comparisons from a 
statistical point of view difficult to interpret. 
Nevertheless, the study emphasizes the importance of investigating the cause of significant 
lymphadenopathy in HIV seropositive individuals, as in 65% of such individuals a 
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pathological cause such as TB or malignancy is found.  The high discordance rates of 33,3%  
between the FNA and the lymph node biopsy, underlines the fact that a lymph node biopsy 
should remain the investigation of choice, where a definitive diagnosis needs to be 
established, particularly with respect to malignancy. 
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